ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,814.40
-0.85%
S&P ASX All Technology
3,045.20
-2.07%
Brent Oil
83.725
0.62%
US Dollar vs AUD
1.49343
-0.22%
Bitcoin
66,919.21
2.58%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Entera Bio Ltd (ENTX)

  7. Entera Bio Ltd (ENTX) News

ENTX

Entera Bio (ENTX)

Entera Bio Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ENTX
DateTimeSourceHeadlineSymbolCompany
15/05/202422:00GlobeNewswire Inc.Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board MemberNASDAQ:ENTXEntera Bio Ltd
13/05/202421:00GlobeNewswire Inc.Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024NASDAQ:ENTXEntera Bio Ltd
11/05/202406:14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ENTXEntera Bio Ltd
11/05/202406:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ENTXEntera Bio Ltd
11/05/202406:10GlobeNewswire Inc.Entera Bio Reports Q1 2024 Financial Results and Provides Business UpdatesNASDAQ:ENTXEntera Bio Ltd
08/04/202422:30GlobeNewswire Inc.Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral ResearchNASDAQ:ENTXEntera Bio Ltd
26/03/202423:30GlobeNewswire Inc.Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 MonthsNASDAQ:ENTXEntera Bio Ltd
20/03/202423:00GlobeNewswire Inc.Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel SyndromeNASDAQ:ENTXEntera Bio Ltd
09/03/202408:25Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ENTXEntera Bio Ltd
09/03/202408:12Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ENTXEntera Bio Ltd
09/03/202408:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ENTXEntera Bio Ltd
09/03/202408:05GlobeNewswire Inc.Entera Bio Announces Full Year 2023 Financial Results and Provides Business UpdatesNASDAQ:ENTXEntera Bio Ltd
05/03/202400:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ENTXEntera Bio Ltd
05/03/202400:30GlobeNewswire Inc.Entera Bio Regains Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:ENTXEntera Bio Ltd
16/02/202409:10Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ENTXEntera Bio Ltd
15/02/202416:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ENTXEntera Bio Ltd
14/02/202422:05Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:ENTXEntera Bio Ltd
03/02/202408:19Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ENTXEntera Bio Ltd
03/02/202408:17Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ENTXEntera Bio Ltd
31/01/202400:30GlobeNewswire Inc.Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:ENTXEntera Bio Ltd
17/01/202400:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTXEntera Bio Ltd
12/01/202410:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTXEntera Bio Ltd
04/01/202410:59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTXEntera Bio Ltd
04/01/202408:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTXEntera Bio Ltd
04/01/202408:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTXEntera Bio Ltd
04/01/202408:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTXEntera Bio Ltd
04/01/202400:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ENTXEntera Bio Ltd
03/01/202409:19Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:ENTXEntera Bio Ltd
28/12/202300:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ENTXEntera Bio Ltd
27/12/202300:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ENTXEntera Bio Ltd
 Showing the most relevant articles for your search:NASDAQ:ENTX

Your Recent History

CSE
STIL
StillCanna
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved